CODX•prnewswire•
Co-Diagnostics JV, CoSara, to Participate at VIROCON 2025 in Pune, India
Summary
Ongoing Phase II preclinical study data for Co-Dx PCR MTB and HPV tests support advancement to clinical performance testing SALT LAKE CITY, Dec. 9, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented...
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on December 8, 2025 by prnewswire